The more evidence behind a therapy, the less the public trusts it

6 hours ago

A patient stopped her statin due to perceived side effects like brain fog and achiness, despite a high coronary artery calcium score and increased LDL, and a family history of heart attack.
She replaced statins with BPC-157, an unregulated synthetic peptide ordered online and injected for a knee injury, based on podcast recommendations and minimal human evidence.
Recent large-scale studies, including a Lancet analysis of 123,940 people, show statins do not cause most alleged side effects and reduce cardiovascular events and mortality significantly.
BPC-157 has very limited human evidence: only 14 participants in total across small studies, no FDA approval, safety concerns, and no rigorous trials in over 30 years.
The trend reflects a consumer health culture where public trust inversely correlates with evidence volume, with patients favoring anecdotal sources over clinical data.
The wellness industry's argument that absence of evidence isn't evidence of absence is misleading, as the lack of BPC-157 trials signals insufficient compelling data.
Trust issues stem from past institutional failures, but responses often shift trust to new financially motivated actors without evidence requirements.
Rebuilding trust requires empathetic doctor-patient conversations about evidence for both established and experimental treatments, not just data presentation.

Hasty Briefsbeta